SAB Biotherapeutics, Inc.
SABS
$1.79
$0.03992.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 114.70K | -- | 263.10K | 944.60K | 305.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.70K | -- | 263.10K | 944.60K | 305.00K |
| Cost of Revenue | 7.65M | 7.83M | 6.82M | 8.15M | 4.30M |
| Gross Profit | -7.54M | -7.83M | -6.56M | -7.20M | -3.99M |
| SG&A Expenses | 2.47M | 3.48M | 3.64M | 4.19M | 14.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.12M | 11.31M | 10.46M | 12.34M | 19.18M |
| Operating Income | -10.01M | -11.31M | -10.20M | -11.39M | -18.87M |
| Income Before Tax | -11.39M | -10.35M | -7.34M | -5.03M | -22.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.39M | -10.35M | -7.34M | -5.03M | -22.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.39M | -10.35M | -7.34M | -5.03M | -22.86M |
| EBIT | -10.01M | -11.31M | -10.20M | -11.39M | -18.87M |
| EBITDA | -9.24M | -10.36M | -9.17M | -9.43M | -17.95M |
| EPS Basic | -1.23 | -1.12 | -0.79 | -0.54 | -3.38 |
| Normalized Basic EPS | -0.77 | -0.70 | -0.50 | -0.34 | -2.11 |
| EPS Diluted | -1.23 | -1.12 | -0.79 | -0.54 | -3.38 |
| Normalized Diluted EPS | -0.77 | -0.70 | -0.50 | -0.34 | -2.11 |
| Average Basic Shares Outstanding | 9.29M | 9.26M | 9.26M | 9.24M | 6.76M |
| Average Diluted Shares Outstanding | 9.29M | 9.26M | 9.26M | 9.24M | 6.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |